LRRK2 inhibitors (Vernalis/H Lundbeck)

N/A

Report date: 2025/01/26 18:25:00
NME

Base Information

Drug NameLRRK2 inhibitors (Vernalis/H Lundbeck)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsNerve DegenerationParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmarkUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVernalis Plc
China Registration ClassN/A

Develop Information

Active CompaniesVernalis PlcH. Lundbeck A/S
Inactive CompaniesN/A
Active IndicationsNerve DegenerationParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A